Cargando…

Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations

AIM: To evaluate the factors influencing suspected hypersensitivity and adverse systemic reactions after Shuxuening injection and to provide innovative ideas and methods for the reevaluation of post-marketing safety of Shuxuening. METHODS: This study used a prospective, nested case–control study des...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Can, Shi, Qing-ping, Ding, Feng, Jiang, Xiao-dong, Tang, Wei, Yu, Mei-Ling, Zhu, Jian-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896674/
https://www.ncbi.nlm.nih.gov/pubmed/29670332
http://dx.doi.org/10.2147/DDDT.S156000
_version_ 1783313859582361600
author Wang, Can
Shi, Qing-ping
Ding, Feng
Jiang, Xiao-dong
Tang, Wei
Yu, Mei-Ling
Zhu, Jian-Hua
author_facet Wang, Can
Shi, Qing-ping
Ding, Feng
Jiang, Xiao-dong
Tang, Wei
Yu, Mei-Ling
Zhu, Jian-Hua
author_sort Wang, Can
collection PubMed
description AIM: To evaluate the factors influencing suspected hypersensitivity and adverse systemic reactions after Shuxuening injection and to provide innovative ideas and methods for the reevaluation of post-marketing safety of Shuxuening. METHODS: This study used a prospective, nested case–control study design, combined with a prescription sequence analysis design method. It classified patients who exhibited trigger signals after administration of Shuxuening injection as suspected allergic patients and made comparisons with patients who did not report adverse effects to calculate the correlation between relevant risk factors and suspected allergic reactions. Randomized controlled studies and cohort studies of the adverse drug reaction (ADR) of Shuxuening were performed using a computer database. Data retrieval was carried out by the foundation governing the individual database. Meta-analysis was performed by using R3.2.3 software to evaluate the ADRs of Shuxuening. RESULTS: The results of real-world study showed that administration of Shuxuening in combination with potassium aspartate and magnesium, atorvastatin calcium, Shengmai injection, pantoprazole sodium, or high-dose medication was a risk factor for suspected allergic reactions. Meta-analysis showed that the incidence of adverse events was 5.84% (95% CI 0.0499; 0.0674), and serious adverse reaction rate was 4.36% (95% CI 0.0188; 0.0760) when Shuxuening was used in combination with these drugs. The incidence of allergic reaction was also influenced by the vehicle, duration of treatment, single dose, and indicated vs off-label use. CONCLUSION: Risk factors for adverse reaction following the use of Shuxuening injection in patients are associated with a single dose, vehicle, type of disease, and combination with potassium aspartate, atorvastatin calcium, Shengmai injection, injection with pantoprazole sodium, and other drugs. Physicians should be careful to follow guidelines when administering this drug. We further propose that the unique methodology used in this study may be useful for reevaluation of the safety of other traditional Chinese medicines.
format Online
Article
Text
id pubmed-5896674
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58966742018-04-18 Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations Wang, Can Shi, Qing-ping Ding, Feng Jiang, Xiao-dong Tang, Wei Yu, Mei-Ling Zhu, Jian-Hua Drug Des Devel Ther Original Research AIM: To evaluate the factors influencing suspected hypersensitivity and adverse systemic reactions after Shuxuening injection and to provide innovative ideas and methods for the reevaluation of post-marketing safety of Shuxuening. METHODS: This study used a prospective, nested case–control study design, combined with a prescription sequence analysis design method. It classified patients who exhibited trigger signals after administration of Shuxuening injection as suspected allergic patients and made comparisons with patients who did not report adverse effects to calculate the correlation between relevant risk factors and suspected allergic reactions. Randomized controlled studies and cohort studies of the adverse drug reaction (ADR) of Shuxuening were performed using a computer database. Data retrieval was carried out by the foundation governing the individual database. Meta-analysis was performed by using R3.2.3 software to evaluate the ADRs of Shuxuening. RESULTS: The results of real-world study showed that administration of Shuxuening in combination with potassium aspartate and magnesium, atorvastatin calcium, Shengmai injection, pantoprazole sodium, or high-dose medication was a risk factor for suspected allergic reactions. Meta-analysis showed that the incidence of adverse events was 5.84% (95% CI 0.0499; 0.0674), and serious adverse reaction rate was 4.36% (95% CI 0.0188; 0.0760) when Shuxuening was used in combination with these drugs. The incidence of allergic reaction was also influenced by the vehicle, duration of treatment, single dose, and indicated vs off-label use. CONCLUSION: Risk factors for adverse reaction following the use of Shuxuening injection in patients are associated with a single dose, vehicle, type of disease, and combination with potassium aspartate, atorvastatin calcium, Shengmai injection, injection with pantoprazole sodium, and other drugs. Physicians should be careful to follow guidelines when administering this drug. We further propose that the unique methodology used in this study may be useful for reevaluation of the safety of other traditional Chinese medicines. Dove Medical Press 2018-04-05 /pmc/articles/PMC5896674/ /pubmed/29670332 http://dx.doi.org/10.2147/DDDT.S156000 Text en © 2018 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wang, Can
Shi, Qing-ping
Ding, Feng
Jiang, Xiao-dong
Tang, Wei
Yu, Mei-Ling
Zhu, Jian-Hua
Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
title Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
title_full Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
title_fullStr Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
title_full_unstemmed Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
title_short Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
title_sort reevaluation of the post-marketing safety of shuxuening injection based on real-world and evidence-based evaluations
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896674/
https://www.ncbi.nlm.nih.gov/pubmed/29670332
http://dx.doi.org/10.2147/DDDT.S156000
work_keys_str_mv AT wangcan reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations
AT shiqingping reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations
AT dingfeng reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations
AT jiangxiaodong reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations
AT tangwei reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations
AT yumeiling reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations
AT zhujianhua reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations